Week in Review: Hengrui's US Spinoff Funded with $100 Million

Hengrui Therapeutics Inc., a New Jersey offshoot of Jiangsu Hengrui Medicine raised $100 million in initial funding from HR Bio Holdings Limited. Initially, HTI will work on US development of three oncology drug candidates from China-Hengrui.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.